Extensive Stage Small Cell Lung Cancer Market – A Global and Regional Analysis: Focus on Epidemiology, Product, and Region – Analysis and Forecast, 2022-2032
$5250 – $8100
The aim of this research study of Extensive Stage Small Cell Lung Cancer is to identify the market in terms of potential patients eligible for available treatments. The report focuses solely on the extensive stage small cell lung cancer treatment, which includes approved products as well as products under clinical development.
Description
Global Extensive Stage Small Cell Lung Cancer Market Overview
Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients. The median overall survival reported among the extensive stage small cell lung cancer patients has been slightly above a year while the overall progression free survival is reported to be of six months. Before the emergence of immune checkpoint inhibitors, traditional chemotherapy which included etoposide in combination with platinum (cisplatin or carboplatin) were the treatment mainstay however since the approval of immune checkpoint inhibitors; these have been included in the standard treatment regimen along with chemotherapy.
The Growing Prevalence of Extensive Stage Small Cell Lung Cnacer
The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study. Geographically, the U.S. remains at the top with an estimated prevalence for 2021 of more than 47,000 patients followed by the U.K. with over 8,500 patients. The prevalence is forecasted to be growing at a CAGR of 2.61% and 1.61% respectively for the U.S. and the U.K for the period 2022-2032.
Competitive Landscape
The current global extensive stage small cell lung cancer market has two approved immune checkpoint inhibitors namely Imfinzi (Durvalumab) from AstraZeneca PLC and Tecentriq (Atezolizumab) from F. Hoffmann La-Roche Ltd. Zepzelca (Lurbinectedine) from Jazz Pharmaceuticals Plc and Cosela (Trilaciclib) from G1 Therapeutics Inc. are other two products approved for the treatment of extensive stage small cell lung cancer patients.
Since, the introduction of immune checkpoint inhibitors to the extensive stage small cell lung cancer treatment, the competition in the global extensive stage small cell lung cancer market has significantly increased. F. Hoffmann La-Roche Ltd. and AstraZeneca Plc are the leading players among the companies having immune checkpoint inhibitor portfolio in the global extensive stage small cell lung cancer market. The companies having immune checkpoint inhibitors under clinical development have also added extensive stage small cell lung cancer treatment to their portfolio.
Currently there are four products available in the market which are patented. The chemotherapeutic products which constituted the standard of care have all become generic. There is a rich clinical pipeline of extensive stage small cell lung cancer maket with dominance of immune checkpoint inhibitors along with CRIpecific antibodies.
Segmentation:
Within the research report, the segmentation has made on the basis of:
• Existing as well as Expected competition in the global extensive stage small cell lung cancer market. Commercial and Clinical products constitute “Products” segment., and
• Region is the other segment which covers the seven major markets (the U.S., the U.K., Germany, France, Italy, Spain, and Japan).
Demand – Drivers and Challenges
Some of the potential drivers identified by CRI Research includes:
• Potential therapeutic effects of immune checkpoint inhibitors in improving overall survival among cancer patients
• Treatment directed toward decreasing the chemotherapy induced toxic effects
There are some challenges identified for the global extensive stage small cell lung cancer market include; treatment related toxic effects, lack of effective diagnostic tools/methods among others.
How can this report add value to an organization?
Product/Innovation Strategy: The report provides an insight into estimated patient population eligible to receive treatment in the seven major market, with a view where the disease is on a decline and where it is showing an increasing trend. Additionally, the report provides an exhaustive list of pipeline products along with their developmental details which are currently in the development for extensive stage small cell lung cancer treatment. This can help organizations in assess the research activities, potential candidates to enter first into the market as well it can help the organization to assess where should they place themselves in order to get maximum benefit.
Growth/Marketing Strategy: The several growth strategies identified in the report include increased focus toward development of immunotherapies, use of immunotherapies in combination with existing standard treatment options, expanding the market reach by entering into licensing agreement with potential players.
Competitive Strategy: Key players in the global extensive stage small cell lung cancer market were analyzed and profiled in the study, who have commercially available treatment for extensive stage small cell lung cancer. Moreover, a detailed competitive benchmarking of the players operating in the global extensive stage small cell lung cancer market has been included to help the reader understand how players stand against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Companies Profiled
• F. Hoffmann-La Roche Ltd
• AstraZeneca PLC
• Jazz Pharmaceuticals Plc
• G1 Therapeutics Inc.
• Shanghai Henlius Biotech, Inc.
• Lee’s Pharmaceutical Limited
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Beigene Ltd.
Table of Contents
1 Market Definition
1.1 Inclusion and Exclusion Criteria
2 Research Scope
2.1 Target Audience
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Global Extensive Stage Small Cell Lung Cancer Market: Research Methodology
3.2 Primary Data Sources
3.3 Secondary Data Sources
3.4 Target Patient Pool Estimation Model
3.5 Criteria for Company Profiling
4 Markets
4.1 Market Overview
4.1.1 Market Landscape
4.1.1.1 Strategic Activities
4.1.1.2 Regional Distribution of Companies
4.1.2 Market Dynamics
4.1.2.1 Market Drivers
4.1.2.1.1 Introduction of Immune Checkpoint Inhibitors in Combination with Platinum-Based Chemotherapy as Mainstay Treatment
4.1.2.1.2 Next-Generation Sequencing is Helping in Identifying New Molecular Targets
4.1.2.1.3 Need of Potential Treatments to Improve Quality of Life of Extensive Stage Small Cell Lung Cancer Patients
4.1.2.2 Market Restraints
4.1.2.2.1 Lack of Early Detection Methods for Extensive Stage Small Cell Lung Cancer
4.1.2.2.2 Poor Disease Prognosis of Extensive Stage Small Cell Lung Cancer
4.1.2.3 Opportunities
4.1.2.3.1 Approval of Immune Checkpoint Inhbitors as Combination Therapy Broadens the Horizon
4.1.2.3.2 Lack of Approved Treatments for Extensive Stage Small Cell Lung Cancer Relapsed Patients
5 Indication
5.1 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
5.1.1 Disease Overview
5.1.2 Causes and Risk Factors
5.1.3 Disease Pathophysiology
5.1.3.1 Disease Staging
5.1.4 Symptoms
5.1.5 Treatment Landscape
5.1.5.1 Treatment Overview
5.1.5.2 Treatment Types
5.1.5.3 Treatment Guidelines for Extensive Stage Small Cell Lung Cancer Patients
5.1.5.4 Treatment Algorithm
5.1.6 Unmet Needs
5.1.6.1 Lack of Therapeutic Efficacy of the Existing Treatments
5.1.6.2 Treatment-Related Side Effects Impacting Overall Quality of Life
5.1.7 Patient Journey
6 Region
6.1 U.S.
6.2 U.K.
6.3 Germany
6.4 France
6.5 Italy
6.6 Spain
6.7 Japan
7 Products
7.1 Global Extensive Stage Small Cell Lung Cancer Market Pipeline Analysis (by Phase)
7.1.1 Development Phase
7.1.2 Drug Class
7.1.3 Route of Administration (RoA)
7.1.4 Monotherapy/Combination Therapy Type
7.2 Marketed Products
7.2.1 Zepzelca (Lurbinectedine)
7.2.1.1 Overview
7.2.1.2 Commercial Overview
7.2.1.2.1 Strategic Activities
7.2.1.2.2 Regulatory Overview
7.2.1.3 Clinical Overview
7.2.2 Cosela (Trilaciclib)
7.2.2.1 Overview
7.2.2.2 Commercial Overview
7.2.2.2.1 Strategic Activities
7.2.2.2.2 Regulatory Overview
7.2.2.3 Clinical Overview
7.2.3 Tecentriq (Atezolizumab)
7.2.3.1 Overview
7.2.3.2 Commercial Overview
7.2.3.3 Clinical Overview
7.2.4 Imfinzi (Durvalumab)
7.2.4.1 Overview
7.2.4.2 Commercial Overview
7.2.4.3 Clinical Overview
7.3 Promising Products in Development
7.3.1 HLX10 (Serplulimab/Hansizhuang)
7.3.1.1 Overview
7.3.1.2 Commercial Overview
7.3.1.2.1 Regulatory Overview
7.3.1.3 Clinical Overview
7.3.2 Socazolimab (ZKAB001)
7.3.2.1 Overview
7.3.2.2 Commercial Overview
7.3.2.2.1 Regulatory Overview
7.3.2.3 Clinical Overview
7.3.3 SHR-1316 (Adebrelimab)
7.3.3.1 Overview
7.3.3.2 Commercial Overview
7.3.3.2.1 Regulatory Overview
7.3.4 Tislelizumab
7.3.4.1 Overview
7.3.4.2 Commercial Overview
7.3.4.3 Clinical Overview
8 Competitive Benchmarking and Company Profiles
8.1 F. Hoffmann-La Roche Ltd
8.1.1 Company Overview
8.1.2 Role of F. Hoffmann-La Roche Ltd in Global Extensive Stage Small Cell Lung Cancer Market
8.1.3 Product Portfolio
8.1.4 Key Competitors of the Company
8.1.5 Financials
8.1.6 Key Insights about the Financial Health of the Company
8.1.7 Business Strategies
8.1.8 Corporate Strategies
8.1.9 Analyst’s Perspective
8.2 AstraZeneca PLC
8.2.1 Company Overview
8.2.2 Role of AstraZeneca PLC in Global Extensive Stage Small Cell Lung Cancer Market
8.2.3 Product Portfolio
8.2.4 Key Competitors of the Company
8.2.5 Financials
8.2.6 Key Insights about the Financial Health of the Company
8.2.7 Business Strategies
8.2.8 Analyst's Perspective
8.3 Jazz Pharmaceuticals Plc
8.3.1 Company Overview
8.3.2 Role of Jazz Pharmaceuticals Plc in Global Extensive Stage Small Cell Lung Cancer Market
8.3.3 Product Portfolio
8.3.4 Key Competitors of the Company
8.3.5 Financials
8.3.6 Key Insights about the Financial Health of the Company
8.3.7 Business Strategies
8.3.8 Corporate Strategies
8.3.9 Analyst’s Perspective
8.4 G1 Therapeutics Inc.
8.4.1 Company Overview
8.4.2 Role of G1 Therapeutics Inc. in Global Extensive Stage Small Cell Lung Cancer Market
8.4.3 Product Portfolio
8.4.4 Key Competitors of the Company
8.4.5 Financials
8.4.6 Key Insights about the Financial Health of the Company
8.4.7 Business Strategies
8.4.8 Corporate Strategies
8.4.9 Analyst’s Perspective
8.5 Shanghai Henlius Biotech, Inc.
8.5.1 Company Overview
8.5.2 Role of Shanghai Henlius Biotech, Inc. in Global Extensive Stage Small Cell Lung Cancer Market
8.5.3 Product Portfolio
8.5.4 Key Competitors of the Company
8.5.5 Financials
8.5.6 Key Insights about the Financial Health of the Company
8.5.7 Business Strategies
8.5.8 Analyst’s Perspective
8.6 Lee's Pharmaceutical Limited
8.6.1 Company Overview
8.6.2 Role of Lee's Pharmaceutical Limited in Global Extensive Stage Small Cell Lung Cancer Market
8.6.3 Product Portfolio
8.6.4 Key Competitors of the Company
8.6.5 Financials
8.6.6 Key Insights about the Financial Health of the Company
8.6.7 Business Strategies
8.6.8 Analyst’s Perspective
8.7 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
8.7.1 Company Overview
8.7.2 Role of Jiangsu Hengrui Pharmaceuticals Co., Ltd. in Global Extensive Stage Small Cell Lung Cancer Market
8.7.3 Product Portfolio
8.7.4 Key Competitors of the Company
8.7.5 Financials
8.7.6 Key Insights about the Financial Health of the Company
8.7.7 Business Strategies
8.7.8 Corporate Strategies
8.7.9 Analyst’s Perspective
8.8 Beigene Ltd.
8.8.1 Company Overview
8.8.2 Role of Beigene Ltd. in Global Extensive Stage Small Cell Lung Cancer Market
8.8.3 Product Portfolio
8.8.4 Key Competitors of the Company
8.8.5 Financials
8.8.6 Key Insights about the Financial Health of the Company
8.8.7 Corporate Strategies
8.8.8 Analyst’s Perspective
9 BIS Research Recommendations
9.1 Current Market Scenario
9.2 Future Scenario
9.3 Key Success Factors and Challenges
9.3.1 Success Factors
9.3.2 Key Challenges
List of Figures
Figure 1: Extensive Stage Small Cell Lung Cancer Incidence Growth Rate, 2022-2032
Figure 2: Extensive Stage Small Cell Lung Cancer Prevalence Growth Rate, 2022-2032
Figure 3: Leading Drug Class in Clinical Trials for Extensive Stage Small Cell Lung Cancer Market
Figure 4: Global Extensive Stage Small Cell Lung Cancer Market Segmentation
Figure 5: Global Extensive Stage Small Cell Lung Cancer Market Methodology
Figure 6: Primary Research Methodology
Figure 7: Companies Actively Pursuing Clinical Development for Extensive Stage Small Cell Lung Cancer
Figure 8: Number of Strategic Activities
Figure 9: Regional Distribution of Companies
Figure 10: Lung Cancer Types
Figure 11: Disease Pathophysiology
Figure 12: Extensive Stage Small Cell Lung Cancer Treatment Types
Figure 13: Extensive Stage Small Cell Lung Cancer Treatment Algorithm
Figure 14: Extensive Stage Small Cell Lung Cancer Patient Journey
Figure 15: U.S. Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 16: U.S. Prevalence of Extensive Stage Small Cell Lung Cancer, 2022-2032
Figure 17: U.K. Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 18: U.K. Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 19: Germany Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 20: Germany Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 21: France Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 22: France Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 23: Italy Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 24: Italy Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 25: Spain Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 26: Spain Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 27: Japan Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 28: Japan Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 29: Number of Extensive Stage Small Cell Lung Cancer Clinical Trials
Figure 30: Clinical Trials by Drug Class
Figure 31: Clinical Trials by Monotherapy/Combination Type
Figure 32: Zepzelca (Lurbinectedine) Annual Sales ($Million), 2020 and 2021
Figure 33: Tecentriq Annual Sales ($Million), 2019-2021
Figure 34: Imfinzi Annual Sales ($Million), 2020 and 2021
Figure 35: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 36: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 37: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021
Figure 38: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 39: AstraZeneca PLC: Product Portfolio
Figure 40: AstraZeneca PLC: Overall Financials, $Million, 2019-2021
Figure 41: AstraZeneca PLC: Net Revenue (by Region), $Million, 2019-2021
Figure 42: AstraZeneca PLC: R&D Expenditure, $Million, 2019-2021
Figure 43: Jazz Pharmaceuticals Plc: Product Portfolio
Figure 44: Jazz Pharmaceuticals Plc: Overall Financials, $Million, 2019-2021
Figure 45: Jazz Pharmaceuticals Plc: R&D Expenditure, $Million, 2019-2021
Figure 46: G1 Therapeutics Inc.: Product Portfolio
Figure 47: G1 Therapeutics Inc.: Overall Financials, $Million, 2019-2021
Figure 48: G1 Therapeutics Inc.: R&D Expenditure, $Million, 2019-2021
Figure 49: Shanghai Henlius Biotech, Inc.: Product Portfolio
Figure 50: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021
Figure 51: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 52: Lee's Pharmaceutical Limited: Product Portfolio
Figure 53: Lee's Pharmaceutical Limited: Overall Financials, $Million, 2019-2021
Figure 54: Lee's Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021
Figure 55: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Product Portfolio
Figure 56: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 57: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 58: Beigene Ltd.: Product Portfolio
Figure 59: Beigene Ltd.: Overall Financials, $Million, 2019-2021
Figure 60: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021
List of Tables
Table 1: Extensive Stage Small Cell Lung Cancer Prevalence in Seven Major Markets, 2022-2032
Table 2: Global Extensive Stage Small Cell Lung Cancer Market Snapshot
Table 3: HLX-10 (Serplulimab/Hansizhuang) from Shanghai Henlius Biotech in Comparison with Approved Products of the Global Extensive Stage Small Cell Lung Cancer Market
Table 4: Jiangsu Hengrui Pharmaceuticals Co., Ltd. Extensive Stage Small Cell Lung Cancer Pipeline
Table 5: Competitive Landscape Snapshot
Table 6: Potential Immune Checkpoint Inhibitors Under Clinical Development
Table 7: Different Drug Classes Under Development for Treatment of Extensive Stage Small Cell Lung Cancer
Table 8: Veterans’ Administration (VA) Lung Group Classification Scheme
Table 9: Advantages and Disadvantages of Chemotherapy Treatment
Table 10: Advantages and Disadvantages of Radiation Therapy
Table 11: FDA Approved Immunotherapies for Treatment of Extensive Stage Small Cell Lung Cancer
Table 12: Advantages and Disadvantages of Immunotherapy
Table 13: NCCN and NICE Treatment Guidelines
Table 14: Clinical Trials by Route of Administration (RoA)
Table 15: Combination Therapies Under Clinical Trial
Table 16: Leading Monotherapies Under Clinical Trial
Table 17: Marketed Products Indicated for the Treatment of Extensive Stage Small Cell Lung Cancer
Table 18: Zepzelca (Lurbinectedine) Key Regulatory Events
Table 19: Promising Products in Development
Table 20: Clinical Trial Details of HLX-10 (Serplulimab/Hansizhuang)
Table 21: Clinical Trial Details of HLX-10
Table 22: Clinical Trial Details of Socazolimab (ZKAB001)
Table 23: Clinical Trial Details of SHR-1316 (Adebrelimab)
Table 24: Phase Three Clinical Trial Result of SHR-1316 (Adebrelimab)
Table 25: F. Hoffmann-La Roche Ltd: Key Competitors
Table 26: AstraZeneca PLC: Key Competitors
Table 27: Shanghai Henlius Biotech, Inc.: Key Competitors
Table 28: Lee's Pharmaceutical Limited: Key Competitors
Table 29: Jiangsu Hengrui Pharmaceuticals Co., Ltd.’s Extensive State SCLC Products’ Clinical Trials
Table 30: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Key Competitors
Table 31: Beigene Ltd.: Key Competitors
Company Mentioned
F. Hoffmann-La Roche Ltd
AstraZeneca PLC
Jazz Pharmaceuticals Plc
G1 Therapeutics Inc.
Shanghai Henlius Biotech, Inc.
Lee's Pharmaceutical Limited
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Beigene Ltd.
Reviews
There are no reviews yet.